1. Home
  2. PLSE vs NUVB Comparison

PLSE vs NUVB Comparison

Compare PLSE & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$29.12

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Nuvation Bio Inc.

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$5.64

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
NUVB
Founded
2014
2018
Country
United States
United States
Employees
N/A
307
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
PLSE
NUVB
Price
$29.12
$5.64
Analyst Decision
Buy
Strong Buy
Analyst Count
1
8
Target Price
$22.00
$11.38
AVG Volume (30 Days)
362.7K
8.3M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$840.00
$203.82
Revenue Next Year
$287.54
$58.18
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.56
$2.06
52 Week High
$31.00
$9.75

Technical Indicators

Market Signals
Indicator
PLSE
NUVB
Relative Strength Index (RSI) 62.68 56.96
Support Level $23.94 $4.13
Resistance Level N/A $6.06
Average True Range (ATR) 2.02 0.39
MACD 0.23 -0.00
Stochastic Oscillator 73.33 47.70

Price Performance

Historical Comparison
PLSE
NUVB

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: